Palvella Therapeutics, Inc. (PVLA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 31 | 26 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -39 | -58 | ||||||
| Net profit | $m | - | -46 | -33 | 19 | -17 | -42 | -62 | -69 |
| EPS reported | $ | -3.71 | -4.83 | ||||||
| Operating cashflow per share | $ | -2.22 | -2.54 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -2.22 | -2.54 | ||||||
| Free cash flow | $m | -25 | -37 | ||||||
| Net debt | $m | -58 | -251 | ||||||
| Book value equity | $m | 28 | - | ||||||
| Book value per share | $ | 2.49 | 15.11 | ||||||
| Number of shares | m | 11.25 | 14.36 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 42.09 | 10.34 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -47.10 | -32.25 | ||||||
| EV/EBITDA LTM | x | -31.21 | -22.41 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -3.54% | -2.75% | ||||||
| FCF Yield | % | -2.12% | -3.10% | ||||||
| Quality | |||||||||
| ROE | % | -149.07% | -47.84% | ||||||
| ROIC | % | -79.73% | -23.88% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -39.50 | -68.25 | ||||||
| Net Debt/EBITDA | x | 1.60 | 3.75 | ||||||
| EBIT/Net interest | x | -6.63 | -7.60 | ||||||
| Net debt/market cap | % | +0.04% | 0.00% | ||||||
| Net debt/Equity | x | -2.06 | - | ||||||
| Gross debt/equity | x | 0.02 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Palvella Therapeutics, Inc. (PVLA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free